Evidence map›Paper›PMID 34209309›Full record

ArticleCancers2021

Crosstalk between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells.

Michele Minopoli, Sabrina Sarno, Lucia Cannella, Salvatore Tafuto, Gosuè Scognamiglio, Michele Gallo, Flavio Fazioli, Rosa Azzaro, Gaetano Apice, Biagio De Angelis and 11 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Histological response to radiotherapy is an early event in myxoid liposarcoma.Virchows Archiv : an international journal of pathology · 2023
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 1 country.

Michele MinopoliNeoplastic Progression Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.ORCID 0000-0002-5407-481X
Sabrina SarnoNeoplastic Progression Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.ORCID 0000-0002-8190-361X
Lucia CannellaMedical Oncology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.
Salvatore TafutoMedical Oncology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.ORCID 0000-0002-3019-354X
Gosuè ScognamiglioPathology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.ORCID 0000-0003-4376-111X
Michele GalloMusculoskeletal Surgery Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.
Flavio FazioliMusculoskeletal Surgery Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.
Rosa AzzaroTransfusion Medicine Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.
Gaetano ApiceMedical Oncology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.
Biagio De AngelisDepartment of Onco-Haematology and Cell and Gene Therapy Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.ORCID 0000-0002-7938-737X
Elena TamboriniDepartment of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
Cecilia GarofaloAdvanced Translational Research Laboratory, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.ORCID 0000-0001-5334-8930
Ymera PignochinoDepartment of Clinical and Biological Sciences, University of Turin, 10124 Torino, Italy.ORCID 0000-0001-5073-8618
Laura MercataliOsteoncology and Rare Tumors Center, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) IRCCS, 47010 Meldola, Italy.
Toni IbrahimOsteoncology and Rare Tumors Center, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) IRCCS, 47010 Meldola, Italy.ORCID 0000-0003-0259-4167
Rita FalcioniDepartment of Research, Diagnosis and Innovative Technology, IRCCS Regina Elena National Cancer Institute, 00128 Rome, Italy.
Beatrice ValentiOncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, 33081 Aviano, Italy.
Roberta MaestroOncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, 33081 Aviano, Italy.ORCID 0000-0002-6642-5592
Katia ScotlandiLaboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.ORCID 0000-0001-6114-9499
Annarosaria De ChiaraPathology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.
Maria Vincenza CarrieroNeoplastic Progression Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITCentro di Riferimento Oncologico · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITBambino Gesù Children's Hospital · ITCandiolo Cancer Institute · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Oncologico Veneto · ITIstituto Ortopedico Rizzoli · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myxoid liposarcoma (MLPS) is the second most common subtype of liposarcoma and has tendency to metastasize to soft tissues. To date, the mechanisms of invasion and metastasis of MLPS remain unclear, and new therapeutic strategies that improve patients' outcomes are expected. In this study, we analyzed by immunohistochemistry the immune cellular components and microvessel density in tumor tissues from patients affected by MLPS. In order to evaluate the effects of primary human MLPS cells on macrophage polarization and, in turn, the ability of macrophages to influence invasiveness of MLPS cells, non-contact and 3D organotypic co-cultures were set up. High grade MLPS tissues were found heavily vascularized, exhibited a CD3, CD4, and CD8 positive T lymphocyte-poor phenotype and were massively infiltrated by CD163 positive M2-like macrophages. Conversely, low grade MLPS tissues were infiltrated by a discrete amount of CD3, CD4, and CD8 positive T lymphocytes and a scarce amount of CD163 positive macrophages. Kaplan-Meier analysis revealed a shorter Progression Free Survival in MLPS patients whose tumor tissues were highly vascularized and heavily infiltrated by CD163 positive macrophages, indicating a clear-cut link between M2-like macrophage abundance and poor prognosis in patients. Moreover, we documented that, in co-culture, soluble factors produced by primary human MLPS cells induce macrophage polarization toward an M2-like phenotype which, in turn, increases MLPS cell capability to spread into extracellular matrix and to cross endothelial monolayers. The identification of M2-like polarization factors secreted by MLPS cells may allow to develop novel targeted therapies counteracting MLPS progression.

Indexed as

myxoid liposarcomatumor associated macrophagestumor-infiltrating lymphocytestumor microenvironment

Identifiers

PMID34209309
PMCPMC8268435
OpenAlexW3176299449

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.